MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The purpose of this Cohort Treatment Plan is to allow access to crizanlizumab (SEG101) for eligible patients diagnosed with sickle cell disease (SCD) to prevent or reduce the frequency of vaso-occlusive crises (VOC). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written patient informed consent must be obtained prior to start of treatment.
Male or female, 18 to 70 years of age (inclusive) on the day of informed consent signature.
Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high performance liquid chromatography (HPLC) [performed locally]. All sickle cell disease genotypes are eligible (HbSS, HbSβ0, HbSC, HbSβ+, and others).
History of reoccurring VOC as assessed by the Treating Physician.
Patients receiving HU/HC, L-glutamine (Endari), erythropoietin stimulating agents or other therapies as prevention therapy and continue to experience VOC while on any of these treatments.
Patients can continue taking the preventive therapy.
Patient is not a candidate to be treated with alternative treatment options or has discontinued alternative treatments due to unacceptable benefit risk as documented by the Treating Physician.
Patient must meet the following laboratory values prior to treatment:
Absolute Neutrophil Count ≥1.0 x 109/L
Platelets ≥75 x 109/L
Hemoglobin (Hgb) ≥4.0 g/dL
Estimated glomerular filtration rate ≥ 45 mL/min
Direct (conjugated) bilirubin ≤2.0 x ULN
Alanine transaminase (ALT) ≤ 3.0 x ULN
ECOG performance status ≤ 2
Patients eligible for this Treatment Plan must not meet any of the following criteria:
Is on a chronic transfusion program as defined by participating in a scheduled (pre-planned) series of transfusions (simple or exchange). Episodic transfusions are permitted.
Contraindication or hypersensitivity to any drug or metabolites from similar class as crizanlizumab drug or to any excipients of the drug formulation.
History of severe hypersensitivity reaction to other monoclonal antibodies, which in the opinion of the Treating Physician may pose an increased risk of serious infusion reaction.
Use of therapeutic anticoagulation (prophylactic doses permitted) or antiplatelet therapy (other than aspirin or NSAIDs) within the 10 days prior to starting treatment
Patient has no acute pathologic processes.
Received a monoclonal antibody or immunomodulatory agent within 1 year of starting treatment, or has documented immunogenicity to a prior biologic.
Pregnant or nursing women
Patients with bleeding disorders
Known history of testing positive for Human Immunodeficiency Virus (HIV) infection
Patients with active Hepatitis B infections (HBsAg positive)
o Note: Patients with antecedent but no active Hepatitis B (i.e. anti-HBc positive, HBsAg and HBV-DNA negative) are eligible
Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)
Has a serious mental or physical illness, which, in the opinion of the Treating Physician would compromise compliance to treatment.
QTcF ≥470 msec prior to treatment
Other protocol-defined inclusion/exclusion criteria may apply